JPH11217333A - Antiallergic agent - Google Patents
Antiallergic agentInfo
- Publication number
- JPH11217333A JPH11217333A JP10033935A JP3393598A JPH11217333A JP H11217333 A JPH11217333 A JP H11217333A JP 10033935 A JP10033935 A JP 10033935A JP 3393598 A JP3393598 A JP 3393598A JP H11217333 A JPH11217333 A JP H11217333A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- antiallergic
- rhodiola
- plant
- plant body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、抗アレルギー剤に
関する。本発明の抗アレルギー剤は、抗アレルギー性食
品等の食品、化粧品やアトピー性皮膚炎用のクリーム等
の医薬部外品、医薬品及びアレルギー性の下痢などを予
防する配合飼料用添加物等に利用可能である。TECHNICAL FIELD The present invention relates to an antiallergic agent. The antiallergic agent of the present invention is used for foods such as antiallergic foods, quasi-drugs such as cosmetics and creams for atopic dermatitis, pharmaceuticals and additives for compound feeds for preventing allergic diarrhea and the like. It is possible.
【0002】[0002]
【従来の技術】現在、アレルギーを予防又は治療する手
段としては、医薬品分野においては、ステロイド系のホ
ルモン剤や非ステロイド系の多くの合成医薬品が開発さ
れている。また、食品や飼料においては、アレルギーの
原因となるアレルゲンの除去に関する開発、すなわち脱
アレルゲン化の方向で研究が進んでいる。2. Description of the Related Art At present, as means for preventing or treating allergies, steroid hormones and many nonsteroidal synthetic drugs have been developed in the pharmaceutical field. In addition, in foods and feeds, research is progressing in the development of removing allergens that cause allergies, that is, in the direction of de-allergenization.
【0003】医薬品においては、薬剤の長期投与による
副作用等の問題があり、食品あるいは飼料においては、
あらゆる食品、飼料原料について脱アレルゲン化するこ
とは不可能であり、たとえ開発されたとしても、味覚上
の問題や製品コストが高くなる等の欠点があった。[0003] In pharmaceuticals, there are problems such as side effects due to long-term administration of the drug.
It is impossible to deallergenize any food or feed material, and even if it is developed, it has drawbacks such as a problem in taste and an increase in product cost.
【0004】さらに、魚油に含まれるEPAやDHA等
の不飽和脂肪酸の抗アレルギー効果や抗炎症効果が知ら
れており、それらの摂取によってアレルギー体質を変え
られる等の報告があるが、そのためには日常的に摂取す
ることが必要であり、短期的に効果をもたらす成分との
適切な組合せ及びその素材が求められていた。[0004] In addition, the antiallergic and antiinflammatory effects of unsaturated fatty acids such as EPA and DHA contained in fish oil are known, and it has been reported that their ingestion can change the allergic constitution. It needs to be taken on a daily basis, and there has been a demand for an appropriate combination with a component having an effect in a short term and its material.
【0005】[0005]
【発明が解決しようとする課題】従って、本発明の目的
は、毒性や副作用が弱く、優れた抗アレルギー効果を発
揮する抗アレルギー剤を提供することである。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide an antiallergic agent which has low toxicity and side effects and exhibits an excellent antiallergic effect.
【0006】[0006]
【課題を解決するための手段】本願発明者らは、鋭意研
究の結果、ロジオラ属植物が、優れた抗アレルギー効果
を発揮する抗アレルギー性物質を植物体内に含むことを
見出し、本発明を完成した。すなわち、本発明は、ロジ
オラ属に属し、抗アレルギー性物質をその植物体内に含
む植物の植物体自体又はその抽出物を有効成分として含
有する抗アレルギー剤を提供する。Means for Solving the Problems As a result of earnest studies, the present inventors have found that a plant of the genus Rhodiola contains an antiallergic substance exhibiting an excellent antiallergic effect in a plant, and completed the present invention. did. That is, the present invention provides an anti-allergic agent containing a plant itself or an extract thereof as an active ingredient, which belongs to the genus Rhodiola and contains an anti-allergic substance in the plant.
【0007】[0007]
【発明の実施の形態】本発明に用いられるロジオラ属植
物の好ましい例として、ロジオラ・サカリネンシス(Rh
odiola sachalinensis)及びロジオラ・イシダエ(Rhod
iola ishidae) 等を挙げることができるが、これに限定されるものでは
ない。ロジオラ・サカリネンシスは紅景天と呼ばれ、双
子葉植物である景天科(べんけいそう科、Crassulacea
e)に属する長年生草本植物である。紅景天の植生は、
海抜1800mから2300mの山岳地帯であり、主に
アジア(中国、日本、朝鮮北部)、ヨーロッパ及び北米
に分布する。BEST MODE FOR CARRYING OUT THE INVENTION As a preferred example of a Rhodiola plant used in the present invention, Rhodiola sacarinensis ( Rh
odiola sachalinensis ) and Rhodiola isidae ( Rhod)
iola ishidae ) and the like, but are not limited thereto. Rhodiola sacarinensis is known as Kojingen, a dicotyledonous plant known as Crassulacea.
It is a long-standing herbaceous plant belonging to e). The vegetation of Hongjing Heaven is
It is a mountainous area from 1800m to 2300m above sea level, and is mainly distributed in Asia (China, Japan, North Korea), Europe and North America.
【0008】本発明においては、ロジオラ属植物の根、
根茎、茎及び葉等、いずれの部位をも利用することがで
きるが、好ましくは根又は根茎を利用する。また、根又
は根茎等の細胞を常法によりカルス培養した培養細胞も
利用することができる。[0008] In the present invention, the root of the plant of the genus Rhodiola,
Any part such as rhizome, stem and leaf can be used, but preferably root or rhizome is used. In addition, cultured cells obtained by callus-culturing cells such as roots or rhizomes by a conventional method can also be used.
【0009】本発明の抗アレルギー剤は、このような
根、根茎、茎及び葉等や培養細胞等の植物体そのもので
あってもよいし、これから抽出した抽出物であってもよ
い。ロジオラ属植物に含まれる抗アレルギー性物質は、
水系溶媒や水溶性の有機溶媒により植物体から抽出する
ことができる。これらの溶媒としては、水、低級脂肪族
アルコール(メタノール、エタノール、プロパノール)
及びこれらの混合物が好ましい。また、酸やアルカリの
水溶液も利用可能である。これらのうち、水、エタノー
ル及びこれらの混合物が特に好ましい。なお、水又は低
濃度のエタノール水溶液で抽出を行う場合には80℃〜
沸点程度の加熱下に行う方が効率良く抽出を行うことが
できる。エタノール又は高濃度のエタノール水溶液(エ
タノール濃度60%以上)の場合には、室温でも効率良
く抽出を行うことができるし、室温から沸点までの任意
の温度で抽出を行うこともできる。抽出時間は、用いる
溶媒や抽出温度に応じて適宜選択されるが、通常、3時
間〜48時間程度である。The antiallergic agent of the present invention may be a plant such as roots, rhizomes, stems and leaves, or cultured cells, or may be an extract extracted therefrom. Antiallergic substances contained in Rhodiola plants are
It can be extracted from plants using an aqueous solvent or a water-soluble organic solvent. These solvents include water, lower aliphatic alcohols (methanol, ethanol, propanol)
And mixtures thereof. Also, an aqueous solution of an acid or an alkali can be used. Of these, water, ethanol and mixtures thereof are particularly preferred. In addition, when performing extraction with water or a low-concentration aqueous ethanol solution, 80 ° C.
Extraction can be performed more efficiently when heating is performed at about the boiling point. In the case of ethanol or a high-concentration aqueous ethanol solution (ethanol concentration of 60% or more), extraction can be performed efficiently even at room temperature, and extraction can be performed at any temperature from room temperature to the boiling point. The extraction time is appropriately selected depending on the solvent used and the extraction temperature, but is usually about 3 to 48 hours.
【0010】植物体そのものを用いる場合には、植物体
を乾燥又は凍結乾燥したものを粉砕したものが飼料や各
種組成物に添加しやすいので好ましい。また、抽出液
は、そのまま製品に添加するか又は減圧乾燥法や凍結乾
燥法等の既知の乾燥法により脱水濃縮し、乾燥物として
利用することが飼料や各種組成物に添加しやすいので好
ましい。乾燥時、乾燥物の形状を良くするためデキスト
リン等の賦形剤を加えることも可能であり、利用形態を
考慮した既知の工程での製造が可能である。When the plant itself is used, a dried or freeze-dried plant is preferably crushed because it is easily added to feed or various compositions. The extract is preferably added to the product as it is, or dehydrated and concentrated by a known drying method such as a reduced-pressure drying method or a freeze-drying method, and is preferably used as a dried product because it is easily added to feeds and various compositions. At the time of drying, an excipient such as dextrin can be added to improve the shape of the dried product, and the production can be performed by a known process in consideration of the form of use.
【0011】本発明の抗アレルギー剤は、経口投与、非
経口投与のいずれにおいても効果を発揮する。非経口投
与としては、皮膚に塗布する等の局所投与、静脈注射、
皮下注射、筋肉注射、経腸投与、点眼、経鼻投与、腹腔
内投与等を挙げることができる。The antiallergic agent of the present invention exerts its effects in both oral and parenteral administration. Parenteral administration includes topical administration such as application to the skin, intravenous injection,
Examples include subcutaneous injection, intramuscular injection, enteral administration, eye drops, nasal administration, intraperitoneal administration and the like.
【0012】本発明の抗アレルギー剤の有効投与量は、
症状や使用目的に応じて適宜選択されるが、エタノール
抽出物の乾燥物として、体重1kg、1日当り、経口投
与の場合には、通常、0.1g〜2g程度であり、非経
口投与の場合には、10mg〜250mg程度である。The effective dose of the antiallergic agent of the present invention is as follows:
Although it is appropriately selected according to the symptoms and intended use, it is usually about 0.1 g to 2 g in the case of oral administration of 1 kg body weight per day as a dry product of the ethanol extract, and in the case of parenteral administration, Is about 10 mg to 250 mg.
【0013】本発明の抗アレルギー剤は、医薬品として
用いる場合には、常法に従い、他の賦形剤と混合して所
望の形態に製剤することができる。また、化粧品やアト
ピー性皮膚炎等に対するクリーム等の医薬部外品に添加
したり、食品や配合飼料に添加することができる。化粧
品やクリーム等に添加する場合の濃度は、特に限定され
ないが、エタノール抽出物の乾燥物として、通常、製品
組成物1g当り10mg〜50mg程度が好ましい。ま
た、食品や配合飼料に添加する場合には、エタノール抽
出物の乾燥物として、通常、食品又は飼料1kg当り2
g〜20g程度が好ましい。When used as a pharmaceutical, the antiallergic agent of the present invention can be mixed with other excipients and formulated into a desired form according to a conventional method. Further, it can be added to quasi-drugs such as cosmetics and creams for atopic dermatitis and the like, and can be added to foods and compound feeds. The concentration when added to cosmetics, creams and the like is not particularly limited, but is preferably about 10 mg to 50 mg per 1 g of the product composition as a dry product of the ethanol extract. In addition, when added to food or compound feed, as an ethanol extract dried product, usually 2 kg per 1 kg of food or feed is used.
g to about 20 g are preferred.
【0014】本発明の抗アレルギー剤は、下記実施例に
おいて具体的に示されるように、抗原刺激によるラット
肥満細胞からのロイコトリエン(LTB4 )やヒスタミ
ンの放出抑制とプロスタグランジンに関与する炎症反応
に対する著しい抑制効果を有する。また、下記実施例に
おいて具体的に記載されるように、本発明の抗アレルギ
ー剤は、急性毒性が経口投与の場合は皆無であり、腹腔
内投与の場合でも非常に低い。また、ステロイド剤等と
は異なり、天然物であるので安全性は高い。The antiallergic agent of the present invention suppresses the release of leukotriene (LTB 4 ) and histamine from rat mast cells upon antigen stimulation and an inflammatory reaction involved in prostaglandin, as specifically shown in the following Examples. Has a remarkable suppressing effect on Further, as specifically described in Examples below, the antiallergic agent of the present invention has no acute toxicity when administered orally, and has a very low acute toxicity even when administered intraperitoneally. Also, unlike steroids and the like, it is a natural product, so its safety is high.
【0015】[0015]
【実施例】以下、本発明を実施例に基づきより具体的に
説明する。もっとも、本発明は下記実施例に限定される
ものではない。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below more specifically based on embodiments. However, the present invention is not limited to the following examples.
【0016】実施例1 抽出乾燥物の調製 紅景天の根茎を乾燥し粉末としたサンプル100gに、
6倍量の70%エタノールを加え、室温で24時間抽出
し、抽出液をろ過した後、その残渣に4倍量の70%エ
タノールを加えさらに24時間抽出し、抽出液をろ過
し、さらにこの操作を繰返して3度の抽出操作を行っ
た。3度の抽出濾液は混合し、減圧濃縮後、70℃で減
圧乾燥することにより15gの乾燥物が得られた。この
抽出乾燥物を抗アレルギー及び抗炎症試験に用いた。 Example 1 Preparation of Dried Extract Extract 100 g of a powdered red rhizome of the red rhizome was
After adding 6 times volume of 70% ethanol, extracting at room temperature for 24 hours and filtering the extract, adding 4 times volume of 70% ethanol to the residue and extracting for another 24 hours, filtering the extract and further extracting the residue. The operation was repeated to perform three extraction operations. The extracted filtrates were mixed three times, concentrated under reduced pressure, and dried at 70 ° C. under reduced pressure to obtain 15 g of a dried product. The dried extract was used for anti-allergy and anti-inflammatory tests.
【0017】実施例2 抽出乾燥物の調製 実施例1と同じ紅景天の乾燥粉末100gに、6倍量の
99.5%エタノールを加え、50℃で振盪しながら1
2時間抽出し、抽出液をろ過後、その残渣について同様
な操作を行い、2度の抽出濾液を混合し、減圧濃縮後、
凍結乾燥して乾燥物16.5gを得た。 Example 2 Preparation of Dried Extract Extract To 6 g of 99.5% ethanol was added to 100 g of the same dry powder of red Kageten as in Example 1, and the mixture was shaken at 50 ° C. for 1 hour.
After extracting for 2 hours, filtering the extract, the same operation is performed on the residue, and the extract filtrate is mixed twice, and concentrated under reduced pressure.
Lyophilization yielded 16.5 g of a dried product.
【0018】実施例3 抽出乾燥物の溶解性 実施例1で得られた抽出乾燥物の各々0.5gを10倍
量の各種溶媒に溶解し、その溶解性を試験した。結果を
下記表1に示す。なお、10倍量の水に溶解した時のp
Hは4.2であった。 Example 3 Solubility of Extracted Dry Product 0.5 g of each of the extracted dried products obtained in Example 1 was dissolved in 10 times the amount of various solvents, and the solubility was tested. The results are shown in Table 1 below. In addition, p when dissolved in 10 times the amount of water
H was 4.2.
【0019】[0019]
【表1】 [Table 1]
【0020】実施例4 抗アレルギー効果 抗アレルギー効果を確認する手段の1つとして、ラット
の肥満細胞からのロイコトリエン(LTB4 )やヒスタ
ミン等の放出抑制効果を見る方法がある。そこで、実施
例1で得られた紅景天の抽出乾燥物の抗アレルギー効果
を確認するため、次の試験を行った。 Example 4 Antiallergic Effect As one of means for confirming the antiallergic effect, there is a method of observing the effect of suppressing the release of leukotriene (LTB 4 ) and histamine from rat mast cells. Therefore, the following test was conducted to confirm the antiallergic effect of the dried and dried red Kagekeiten product obtained in Example 1.
【0021】すなわち、実施例1で得られた紅景天の抽
出乾燥物の10%リン酸緩衝液(PBS)を121℃、
15分間オートクレーブにて加熱後、遠心分離し、その
上清をサンプルとした。ラットは、7週齢Splague Dawr
y 系雄性ラットを使用し、その腹腔内より肥満細胞を含
む腹腔内細胞(以下、「PEC」)を得て、Caイオノ
フォアーの刺激によるLTB4 及びヒスタミンの放出に
対する上記抽出サンプルの抑制効果を見た。この試験は
具体的には次のように行った。That is, a 10% phosphate buffer solution (PBS) of the dried and dried red seaweed extract obtained in Example 1 was heated at 121 ° C.
After heating in an autoclave for 15 minutes, the mixture was centrifuged, and the supernatant was used as a sample. Rats are 7 week old Splague Dawr
Using y male rats, intraperitoneal cells including mast cells (hereinafter, “PEC”) were obtained from the peritoneal cavity, and the inhibitory effect of the extracted sample on the release of LTB 4 and histamine by stimulation of Ca ionophore was examined. Was. This test was specifically performed as follows.
【0022】すなわち、ラットをエーテル麻酔で致死さ
せ、その腹腔内にTyrode液30mlを注入し、腹部を2
分間マッサージした後、開腹し、Tyrode液を回収した。
回収液は200g、5分間遠心し上清除去後、以下の実
験にあわせTyrode液で細胞数を調製し、以下の実験に用
いた。That is, a rat was sacrificed by ether anesthesia, 30 ml of Tyrode's solution was injected into the abdominal cavity, and the abdomen was removed.
After massaging for a minute, the abdomen was opened and the Tyrode solution was collected.
The collected solution was centrifuged at 200 g for 5 minutes, and the supernatant was removed. The number of cells was adjusted with a Tyrode solution according to the following experiment and used for the following experiment.
【0023】LTB4 の測定は、Tyrode液854μl、
紅景天抽出液(10%PBS抽出液)10μl、50μ
M−Caイオノフォア液100μl、25mM−CaC
l2液36μlを混合したものを反応液として用意し
た。The measurement of LTB 4 was performed using 854 μl of Tyrode solution,
Red Kageten extract (10% PBS extract) 10μl, 50μ
100 μl of M-Ca ionophore solution, 25 mM-CaC
a mixture of l 2 solution 36μl were prepared as a reaction solution.
【0024】あらかじめ用意した2×106 細胞/ml
のPEC 1mlを200g、5分間遠心し、上清除去
後、反応液50μlを加え37℃、20分間培養した。
培養後、アセトニトリル・メタノール混合液(6:5)
50μlを添加し、反応を停止した。反応停止後、12,0
00 rpmで10分間遠心分離して上清を得、HPLCによ
るLTB4 の定量に供した。2 × 10 6 cells / ml prepared in advance
Was centrifuged at 200 g for 5 minutes, and after removing the supernatant, 50 μl of the reaction solution was added, followed by culturing at 37 ° C. for 20 minutes.
After cultivation, acetonitrile / methanol mixture (6: 5)
The reaction was stopped by adding 50 μl. After stopping the reaction, 12,0
00 were centrifuged 10 minutes at rpm to obtain a supernatant, it was subjected to determination of LTB 4 by HPLC.
【0025】ヒスタミンは、Tyrode液で106 細胞/m
lに調製したPEC 1ml、紅景天抽出物(10%P
BS抽出液)250μl、50μM−Caイオノフォア
250μl、25mMのCaCl2 液90μl、及びTy
rode液910μlを混合し、37℃、20分間培養後、
氷冷して反応を停止した。反応停止後、4℃、200
g、5分間遠心し、その上清を蛍光分析法によるヒスタ
ミンの定量に供した。Histamine is 10 6 cells / m in Tyrode solution.
1 ml of PEC prepared in 1 liter,
BS extract) 250 μl, 50 μM-Ca ionophore 250 μl, 25 mM CaCl 2 solution 90 μl, and Ty
After mixing 910 μl of the rode solution and culturing at 37 ° C. for 20 minutes,
The reaction was stopped by cooling on ice. After stopping the reaction, 4 ° C, 200
g, and centrifuged for 5 minutes, and the supernatant was subjected to quantification of histamine by fluorescence analysis.
【0026】結果を下記表2に示す。表2に示されるよ
うに、紅景天の抽出サンプルで処理したPECからのL
TB4 及びヒスタミンの放出量は、対照(生理食塩水)
と比べてLTB4 では2%以下に、ヒスタミンでは約1
0%以下に低下し、これらのアレルギー作用物質のPE
Cからの放出を著しく抑制することが確認された。The results are shown in Table 2 below. As shown in Table 2, L from PEC treated with the extracted sample of Hongjing Heaven
Release of TB 4 and histamine control (saline)
Less than 2% in the LTB 4 as compared to, the histamine approximately 1
0% or less, the PE of these allergic substances
It was confirmed that release from C was significantly suppressed.
【0027】[0027]
【表2】 *:対照区に対して有意差(P<0.05) 有り[Table 2] *: Significantly different from control (P <0.05)
【0028】実施例5 抗炎症効果 ラット肥満細胞を用いた実験系で、紅景天の抽出乾燥物
がアレルギー反応を惹起するLTB4 やヒスタミンの肥
満細胞からの放出を抑制することが実施例4で認められ
た。そこで、アレルゲンによる実験的炎症反応を抑制す
るかどうかを確認するため、次の試験を行った。[0028] Example 5 in experimental system using an anti-inflammatory effect rat mast cells, LTB 4 and implementation is possible to suppress the release from mast cells of histamine Example 4 dry extract of Benikeiten to elicit an allergic reaction Was recognized. Therefore, the following test was performed to confirm whether or not the experimental inflammatory response caused by an allergen was suppressed.
【0029】すなわち、実施例1で得られた紅景天の抽
出乾燥物を10%含有する生理食塩水を121℃、15
分間オートクレーブし、サンプル液として供試した。ラ
ットは、6週齢のSD系雄性ラットを用い、その腹腔内
にサンプル液0.5ml〜1mlを投与後、30分間放
置し、右の後股足の甲の厚さをダイヤルゲージで測定し
た。次に1%λ−カラゲニン含有生理食塩水0.1ml
をラットの右後股足に皮下注射し、浮腫を惹起させ、λ
−カラゲニン接種2、3、4、5時間後に、右の後股足
の甲の厚さをダイヤルゲージで測定した。炎症率の算出
は、λ−カラゲニン接種後の右後股足の甲の厚さから、
接種前の厚さを引き、生理食塩水接種の場合の値を10
0として、サンプル液の炎症率を算出した。That is, a physiological saline solution containing 10% of the dried and dried extract of Kokukeiten obtained in Example 1 was heated at 121 ° C. and 15 ° C.
The mixture was autoclaved for minutes, and used as a sample solution. The rats were 6-week-old SD male rats, and 0.5 ml to 1 ml of the sample solution was administered intraperitoneally, allowed to stand for 30 minutes, and the thickness of the instep of the right hind leg was measured with a dial gauge. . Then, 0.1 ml of physiological saline containing 1% λ-carrageenin
Was injected subcutaneously into the right hind leg of the rat to induce edema and λ
-2, 3, 4, 5 hours after carrageenin inoculation, the thickness of the instep of the right hind foot was measured with a dial gauge. The inflammation rate was calculated from the thickness of the instep of the right hind foot after inoculation of λ-carrageenin,
Subtract the thickness before inoculation and subtract the value for saline inoculation by 10
The inflammation rate of the sample solution was calculated as 0.
【0030】結果を下記表3に示す。表3に示されるよ
うに、紅景天のエタノール抽出物は、λ−カラゲニンに
よる実験的炎症反応に対して著効が認められた。本試験
は、プロスタグランジン生合成阻害剤であるインドメタ
シンのカラゲニン足浮腫に対する抑制作用と同様な効果
を示し、実施例4の肥満細胞からのLTB4 放出抑制効
果とともに紅景天の抗炎症能を証明するものである。The results are shown in Table 3 below. As shown in Table 3, the ethanol extract of Hongjingtian showed a remarkable effect on the experimental inflammatory reaction caused by λ-carrageenin. This study showed the same effect as suppressing action to carrageenan paw edema indomethacin prostaglandin biosynthesis inhibitors, anti-inflammatory potential of Benikeiten with LTB 4 release inhibition effect from mast cells of Example 4 Proof.
【0031】[0031]
【表3】 [Table 3]
【0032】実施例6 急性毒性(腹腔内投与) 実施例1で得られた紅景天の抽出乾燥物の腹腔内投与に
おける急性毒性を調べた。すなわち、平均体重23.7
9gのICR系マウスの雄(32日齢)に、下記表4に
示す各濃度水準当り6頭ずつを供試し、マウス腹腔内に
紅景天抽出乾燥物の溶液を接種し、接種日から7日間観
察し、死亡率及び生存率を算出した。プロビット法によ
り算出したLD50は、3810 mg/kg体重であり、極めて低
毒性であった。 Example 6 Acute toxicity (intraperitoneal administration) [0032] The acute toxicity of intraperitoneal administration of the extract of the dried red Kagekeiten obtained in Example 1 was examined. That is, the average weight is 23.7.
9 g of ICR mouse males (32 days old) were tested with 6 mice at each concentration level shown in Table 4 below, and inoculated with the solution of the dried extract of Kokukeiten extract into the peritoneal cavity of the mice. Observations were made for days, and mortality and survival rates were calculated. The LD 50 calculated by the probit method was 3810 mg / kg body weight, which was extremely low toxicity.
【0033】[0033]
【表4】 [Table 4]
【0034】実施例7 急性毒性(経口投与) 実施例1で得られた紅景天のエタノール抽出乾燥物の経
口投与における急性毒性を調べた。すなわち、平均体重
28.31gのICR系マウスの雄(5週齢)10頭
に、体重比に換算して5000 mg/kg体重となるようサンプ
ルを調製し、141.55 mg/0.5 ml/ 頭ずつ胃ゾンデを用い
て強制投与し、投与後の死亡数及び臨床所見を7日間観
察した。その結果、5000 mg/kg体重の1用量で全頭生存
し、死亡及び臨床的異常は認められず、無毒であった。 Example 7 Acute toxicity (oral administration) [0034] The acute toxicity of the ethanol-extracted dried product of Kokukeiten obtained in Example 1 in oral administration was examined. That is, a sample was prepared from 10 male (5 week-old) ICR mice having an average body weight of 28.31 g so as to have a weight ratio of 5000 mg / kg body weight. Gavage was performed using a sonde, and the number of deaths and clinical findings after the administration were observed for 7 days. As a result, all the animals survived at one dose of 5000 mg / kg body weight, did not show any death or clinical abnormality, and were nontoxic.
【0035】[0035]
【発明の効果】以上のごとく、本発明によれば、低毒性
で優れた抗アレルギー作用及び抗炎症作用を有する抗ア
レルギー剤が提供された。As described above, according to the present invention, an anti-allergic agent having low toxicity and excellent anti-allergic and anti-inflammatory effects was provided.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 鮫ケ井 靖雄 千葉県佐倉市上志津1789ー3 ハーモニー 志津B201 (72)発明者 濱野 厚 茨城県稲敷郡茎崎町高見原1丁目5―67 (72)発明者 丹治 藤治 東京都目黒区柿の木坂3―7―16 ──────────────────────────────────────────────────続 き Continuing from the front page (72) Inventor Yasuo Samegai 1789-3 Kamishizu, Sakura-shi, Chiba Harmony Shizu B201 (72) Inventor Atsushi Hamano 1-67-67 Takamihara, Kamizakicho, Inashiki-gun, Ibaraki-pref. Inventor Fujiharu Tanji 3-7-16 Kakinokizaka, Meguro-ku, Tokyo
Claims (3)
をその植物体内に含む植物の植物体自体又はその抽出物
を有効成分として含有する抗アレルギー剤。1. An anti-allergic agent comprising, as an active ingredient, a plant itself or an extract thereof, which belongs to the genus Rhodiola and contains an anti-allergic substance in the plant.
ノール又はこれらの混合物で抽出することにより得られ
たものである請求項1記載の抗アレルギー剤。2. The antiallergic agent according to claim 1, wherein the active ingredient is obtained by extracting the plant with water, ethanol, or a mixture thereof.
である請求項1又は2記載の抗アレルギー剤。3. The antiallergic agent according to claim 1, wherein the plant is Rhodiola sacarinensis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10033935A JPH11217333A (en) | 1998-01-30 | 1998-01-30 | Antiallergic agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10033935A JPH11217333A (en) | 1998-01-30 | 1998-01-30 | Antiallergic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11217333A true JPH11217333A (en) | 1999-08-10 |
Family
ID=12400377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10033935A Pending JPH11217333A (en) | 1998-01-30 | 1998-01-30 | Antiallergic agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH11217333A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2405335A (en) * | 2003-08-28 | 2005-03-02 | Coletica | Use of Rhodiola crenulata extract via the topical route |
KR100834049B1 (en) | 2006-11-13 | 2008-05-30 | 황백 | Medium and method for cell suspension culture of Rhodiloa sachalinensis, and feed additives and feeds containing Rhodiloa sachalinensis cells obtained from the same |
KR100932849B1 (en) | 2007-12-20 | 2009-12-21 | 강원대학교산학협력단 | Manufacturing Method of Chamdol Root Extract |
US20100112097A1 (en) * | 2008-11-03 | 2010-05-06 | Jong Hyun Nam | Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer |
-
1998
- 1998-01-30 JP JP10033935A patent/JPH11217333A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2405335A (en) * | 2003-08-28 | 2005-03-02 | Coletica | Use of Rhodiola crenulata extract via the topical route |
GB2405335B (en) * | 2003-08-28 | 2006-03-08 | Coletica | Use of rhodiola crenulata extract via the topical route |
KR100834049B1 (en) | 2006-11-13 | 2008-05-30 | 황백 | Medium and method for cell suspension culture of Rhodiloa sachalinensis, and feed additives and feeds containing Rhodiloa sachalinensis cells obtained from the same |
KR100932849B1 (en) | 2007-12-20 | 2009-12-21 | 강원대학교산학협력단 | Manufacturing Method of Chamdol Root Extract |
US20100112097A1 (en) * | 2008-11-03 | 2010-05-06 | Jong Hyun Nam | Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5538611B2 (en) | Maillard reaction inhibitor | |
JP6656316B2 (en) | How to use cucumbers, how to use cucumbers extract and how to use drug mixtures | |
Chawla et al. | A review of chemistry and biological activities of the genus Aerva--a desert plant | |
JP2008169174A (en) | Bergenin derivative having inflammatory cytokine production-inhibiting action, food preparation, cosmetic, antiinflammatory agent comprising the same | |
WO2000039249A1 (en) | Ume extract having medicinal effects and compositions containing the same | |
JP2006124350A (en) | Nmf production promoter | |
JP2016160198A (en) | Kaempferia parviflora-containing compositions | |
KR102065469B1 (en) | Composition comprising extract of osmanthus fragrans var. aurantiacus having anti-oxidant or anti-inflammation | |
KR101348729B1 (en) | Eudesman compounds, thereof and compositions for containing the same as an active ingredient | |
JP4837686B2 (en) | Supercritical extract, method for producing the same, method for detecting the same, food and beverage, cosmetics and pharmaceuticals containing the same | |
AU2016201841B2 (en) | Medical Composition Containing Stauntonia Hexaphylla Extract | |
KR101167589B1 (en) | Anti-inflammatory agent containing stauntonia hexaphylla fruit extract | |
KR20080096162A (en) | Cosmetic composition for whitening skin | |
JPH11217333A (en) | Antiallergic agent | |
KR102086854B1 (en) | Anti-oxidant or anti-inflammatory cosmetic compositions containing the plants extract of Cyperaceae | |
JP4460420B2 (en) | Collagen production promoter | |
KR101491493B1 (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
JP3827593B2 (en) | Topical skin preparation | |
JP2003171307A (en) | Matrix metalloprotease inhibitor | |
JP5649995B2 (en) | Ceramide production promoter | |
KR20160125093A (en) | Method for Seperation of Compound Derived from Ginseng and Composition for anti-inflammatory Using the same | |
JP3156224B2 (en) | Anti-inflammatory agent | |
JP2009001514A (en) | Anethole derivative having inflammatory cytokine production-inhibiting action, and food preparation, cosmetic and antiinflammatory agent comprising the same | |
JP2006016340A (en) | Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient | |
KR20190142672A (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract |